Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.54 |
| ▸ | SORD | Q00796 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992966 | 0.80 | SCD (0.58) | DRD2HTR1AHTR2ADRD3 | |
| SCHEMBL27571765 | 0.78 | HCAR2 (0.65) | HCAR2KDM4EMAPTDRD2HTR1A | |
| SCHEMBL993819 | 0.76 | HRH4 (0.54) | SORD | |
| SCHEMBL11637734 | 0.74 | KDM4E (0.65) | HCAR2SORDKDM4EMAPTDRD2 | |
| SCHEMBL20021209 | 0.74 | CYP1A2 (0.53) | — | |
| SCHEMBL992832 | 0.73 | SMN1; SMN2 (0.56) | SORDMAPT | |
| SCHEMBL24937833 | 0.72 | HCAR2 (0.56) | HCAR2SORDKDM4EMAPT | |
| SCHEMBL994567 | 0.72 | ALDH1A1 (0.53) | KDM4EHTR1A | |
| SCHEMBL4558892 | 0.72 | KDM4E (0.71) | SORDKDM4EMAPTDRD2HTR1A | |
| SCHEMBL22955581 | 0.72 | KDM4E (0.61) | HCAR2SORDKDM4EMAPTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804799-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | claimed |
| US-7592343-B2 | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2009-09-22 | — | — | US | claimed |
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | US | claimed |
| EP-1804799-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-07-11 | — | — | EP | claimed |
| WO-2006101521-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-09-28 | — | — | WO | claimed |
| EP-1804799-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | disclosed |
| US-8026360-B2 | Substituted pyridazines as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| EP-2269610-A2 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2011-01-05 | — | — | EP | disclosed |
| US-20090306090-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-12-10 | — | — | US | disclosed |
| US-7592343-B2 | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2009-09-22 | — | — | US | disclosed |
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | US | disclosed |
| EP-1804799-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006101521-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | SCD, SCD5, NR1H2 | HCAR2 370/4885SORD 395/4885KDM4E 901/4885 |
| US-20090306090-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, FADS2 | HCAR2 226/4885SORD 732/4885KDM4E 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.